JP2010116400A5 - - Google Patents

Download PDF

Info

Publication number
JP2010116400A5
JP2010116400A5 JP2009284587A JP2009284587A JP2010116400A5 JP 2010116400 A5 JP2010116400 A5 JP 2010116400A5 JP 2009284587 A JP2009284587 A JP 2009284587A JP 2009284587 A JP2009284587 A JP 2009284587A JP 2010116400 A5 JP2010116400 A5 JP 2010116400A5
Authority
JP
Japan
Prior art keywords
polymorphism
stem cells
ccr5
composition
ccr5δ32
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009284587A
Other languages
English (en)
Japanese (ja)
Other versions
JP5675088B2 (ja
JP2010116400A (ja
Filing date
Publication date
Priority claimed from US09/998,832 external-priority patent/US20030099621A1/en
Application filed filed Critical
Publication of JP2010116400A publication Critical patent/JP2010116400A/ja
Publication of JP2010116400A5 publication Critical patent/JP2010116400A5/ja
Application granted granted Critical
Publication of JP5675088B2 publication Critical patent/JP5675088B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009284587A 2001-11-29 2009-12-15 Hiv感染に対する幹細胞スクリーニングおよび移植治療 Expired - Lifetime JP5675088B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/998,832 US20030099621A1 (en) 2001-11-29 2001-11-29 Stem cell screening and transplantation therapy for HIV infection
US09/998,832 2001-11-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003546840A Division JP2005519877A (ja) 2001-11-29 2002-11-27 Hiv感染のための幹細胞スクリーニングおよび移植治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012215505A Division JP5829993B2 (ja) 2001-11-29 2012-09-28 Hiv感染に対する幹細胞スクリーニングおよび移植治療

Publications (3)

Publication Number Publication Date
JP2010116400A JP2010116400A (ja) 2010-05-27
JP2010116400A5 true JP2010116400A5 (enExample) 2011-03-31
JP5675088B2 JP5675088B2 (ja) 2015-02-25

Family

ID=25545599

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003546840A Withdrawn JP2005519877A (ja) 2001-11-29 2002-11-27 Hiv感染のための幹細胞スクリーニングおよび移植治療
JP2009284587A Expired - Lifetime JP5675088B2 (ja) 2001-11-29 2009-12-15 Hiv感染に対する幹細胞スクリーニングおよび移植治療
JP2012215505A Expired - Fee Related JP5829993B2 (ja) 2001-11-29 2012-09-28 Hiv感染に対する幹細胞スクリーニングおよび移植治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003546840A Withdrawn JP2005519877A (ja) 2001-11-29 2002-11-27 Hiv感染のための幹細胞スクリーニングおよび移植治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012215505A Expired - Fee Related JP5829993B2 (ja) 2001-11-29 2012-09-28 Hiv感染に対する幹細胞スクリーニングおよび移植治療

Country Status (5)

Country Link
US (2) US20030099621A1 (enExample)
EP (1) EP1469888B1 (enExample)
JP (3) JP2005519877A (enExample)
AU (1) AU2002353006A1 (enExample)
WO (1) WO2003045335A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101042448B1 (ko) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
WO2007016372A2 (en) * 2005-07-28 2007-02-08 Eden Biotech Ltd. Method for regenerating an immune system
PT3255061T (pt) * 2006-11-03 2021-07-26 Univ Leland Stanford Junior Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto
PT2164993T (pt) 2007-05-29 2017-01-12 Reid Christopher B Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih
CA2840540A1 (en) * 2011-06-29 2013-01-03 Ronilu Development Corporation Prevention and treatment of hiv infection
WO2014151994A1 (en) 2013-03-15 2014-09-25 Kambiz Shekdar Genome editing using effector oligonucleotides for therapeutic treatment
RU2563172C1 (ru) * 2014-11-12 2015-09-20 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" СПОСОБ ОПРЕДЕЛЕНИЯ АЛЛЕЛЬНОГО ПОЛИМОРФИЗМА CCR5 delta 32
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CA3053129A1 (en) * 2017-02-10 2018-08-16 Abraham J And Phyllis Katz Cord Blood Foundation Methods of treating hiv infection with allogeneic ccr5 null umbilical cord blood cells
ES2954311T3 (es) * 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
CA3082404A1 (en) * 2017-11-15 2019-05-23 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
EP0491873A4 (en) * 1989-09-14 1992-10-28 Board Of Regents, The University Of Texas System Therapeutic compositions; methods for treatment of hiv infections
US6217867B1 (en) * 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
ATE329022T1 (de) * 1997-08-14 2006-06-15 Us Gov Health & Human Serv Verzögerter fortschritt von aids durch missense allel des ccr2 gens
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
AU2001243145A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20030017587A1 (en) * 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro

Similar Documents

Publication Publication Date Title
Beeravolu et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta
JP2024041964A (ja) 胎盤幹細胞を使用する疼痛の治療
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
RU2017118312A (ru) Способы и препараты для трансфекции клеток
RU2018106515A (ru) Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
NZ587809A (en) Use of mesenchymal stem cells expressing cd73 and/or cd105 for treating genetic diseases and disorders
EP2641911A3 (en) Compositions and methods for re-programming cells without genetic modification
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
CN104877967A (zh) 一种过表达Nrf2基因的细胞株MSCs及其制备方法及应用
CN111647604A (zh) 特异性识别猪COL1A1基因的gRNA及其生物材料、试剂盒和应用
WO2011028880A3 (en) Methods for enhancing genome stability and telomere elongation in embryonic stem cells
Balaji et al. CYP1A1 genotypes and haplotypes and risk of oral cancer: A case-control study in South Indians
CN1172926C (zh) 黄芪毛蕊异黄酮及其糖甙在制备具有抗心肌缺血作用药物中的应用
JP2012507997A5 (enExample)
WO2007116408A3 (en) Pluripotent stem cells characterized by expression of germline specific genes
CN107254551A (zh) 一种鉴定和选育PERV‑pol基因缺陷型五指山小型猪近交系新品系的方法
Sato et al. Efficient CRISPR/Cas9-based gene correction in induced pluripotent stem cells established from fibroblasts of patients with sickle cell disease
CN103695467B (zh) 过表达金属硫蛋白的hASCs构建方法及其应用
JP4652139B2 (ja) 超低増殖性細胞株
CN102690828B (zh) 与猪免疫性状相关的cxcl12基因片段克隆及作为分子标记的应用
John et al. Sperm mitochondrial DNA
CN1686566A (zh) Cark基因在制备治疗心肌肥厚药物中的应用及一种抑制心肌肥厚的药物
CN101250529B (zh) 马传染性贫血病毒可溶性受体、其编码序列、其应用
Hardouin et al. Base editing of β0 thalassemia mutations as a therapeutic strategy for β-hemoglobinopathies: efficacy and genotoxicity studies
Sufyanova et al. Genetic Basis for Severe COVID-19